An advanced fat-loss stack pairing tirzepatide with the amylin analogue cagrilintide — different mechanisms, additive appetite control.
Unlike stacking two GLP-1/GIP agonists (which we flag as an avoid-pair), pairing an incretin with an amylin analogue is mechanistically distinct and is being actively trialled (the 'CagriSema'-style approach). Tirzepatide handles the GIP/GLP-1 axis; cagrilintide adds amylin-receptor agonism for satiety and gastric emptying.
This is an advanced stack — two injectables, more side-effect surface, and slower titration. Start each agent separately and low. As always, run with protein and resistance training to defend lean mass.
| Compound | Role | Dose | Frequency |
|---|---|---|---|
| Tirzepatide GIP/GLP-1 axis; titrate slowly. | Primary | 2.5mg starting, titrate up to 5-15mg weekly | Once weekly (same day each week) |
| Cagrilintide Amylin analogue; additive satiety, distinct mechanism. | Primary | 2.4mg weekly (after escalation) | Once weekly, same day each week |